Loading...
Anogenital infection with human papillomavirus (HPV) causes both genital warts and cervical cancer in women; HPV types 16 and 18 are responsible for approximately 70% of cervical cancers worldwide. A three-dose quadrivalent vaccine (HPV types 6, 11, 16, and 18) was licensed in the U.S. in June 2006, based partly on interim results from two manufacturer-sponsored, prospective, placebo-controlled trials. Now, investigators report longer-term results from those trials.
The first trial involved 5455 women aged 16 to 24 in 16 countries. Analyses performed approximately 2.5 years after the vaccine series was completed showed the vaccine to be 100% efficacious in preventing anogenital intraepithelial lesions or warts (0 vs. 60 cases), as well as ce…